Peter Lamb Biography and Net Worth

EVP of Exelixis

Peter Lamb, Ph.D., has served as Executive Vice President, Scientific Strategy and Chief Scientific Officer since February 2016. Previously, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. He has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. He has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.

What is Peter Lamb's net worth?: The estimated net worth of Peter Lamb is at least $13.68 million as of December 15th, 2022. Dr. Lamb owns 410,958 shares of Exelixis stock worth more than $13,680,792 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Lamb may own. Learn More about Peter Lamb's net worth.
How do I contact Peter Lamb?: The corporate mailing address for Dr. Lamb and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Peter Lamb's contact information.
Has Peter Lamb been buying or selling shares of Exelixis?: Peter Lamb has not been actively trading shares of Exelixis during the last ninety days. Most recently, Peter Lamb sold 20,000 shares of the business's stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $15.88, for a transaction totalling $317,600.00. Following the completion of the sale, the executive vice president now directly owns 410,958 shares of the company's stock, valued at $6,526,013.04. Learn More on Peter Lamb's trading history.
Who are Exelixis' active insiders?: Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?: In the last year, Exelixis insiders bought shares 3 times. They purchased a total of 615,000 shares worth more than $12,668,000.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 739,715 shares worth more than $21,619,607.83. The most recent insider tranaction occured on November, 29th when EVP Jeffrey Hessekiel sold 60,000 shares worth more than $2,200,200.00. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.
Information on this page was last updated on 11/29/2024.

Peter Lamb Insider Trading History at Exelixis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2022	Sell	20,000	$15.88	$317,600.00	410,958
12/15/2021	Sell	47,500	$17.44	$828,400.00
11/15/2021	Sell	47,500	$18.09	$859,275.00
10/15/2021	Sell	47,500	$21.92	$1,041,200.00
8/16/2021	Sell	55,000	$18.44	$1,014,200.00
7/15/2021	Sell	60,000	$17.47	$1,048,200.00
6/17/2021	Sell	60,000	$22.18	$1,330,800.00
4/1/2021	Sell	60,000	$22.96	$1,377,600.00
3/1/2021	Sell	65,000	$22.11	$1,437,150.00
2/1/2021	Sell	65,000	$22.08	$1,435,200.00
1/4/2021	Sell	65,000	$20.32	$1,320,800.00
12/18/2020	Sell	65,000	$20.01	$1,300,650.00
6/8/2020	Sell	26,000	$22.56	$586,560.00
4/6/2020	Sell	50,000	$17.26	$863,000.00
6/17/2019	Sell	217,404	$20.59	$4,476,348.36
6/13/2019	Sell	27,596	$20.03	$552,747.88
1/3/2017	Sell	70,000	$14.65	$1,025,500.00
12/1/2016	Sell	70,000	$16.66	$1,166,200.00
10/16/2015	Sell	51,549	$5.80	$298,984.20	36,473
10/13/2015	Sell	600	$5.80	$3,480.00	36,473
10/12/2015	Sell	300,276	$5.84	$1,753,611.84	36,473

Peter Lamb Buying and Selling Activity at Exelixis

Exelixis Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Today's Range

Now: $33.29

$33.11

$33.68

50 Day Range

MA: $33.51

$26.24

$36.46

2 Week Range

Now: $33.29

$19.20

$36.97

Volume

7,648,822 shs

Average Volume

2,082,318 shs

Market Capitalization

$9.51 billion

P/E Ratio

21.34

Dividend Yield

N/A

Beta

0.52

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.